Marlene Cereceres
Medical · Midland, TXNPI 1649825001
Payments from drug & device makers
Across 120 payments — averaging $25.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$429
- Novo Nordisk$428
- AstraZeneca$327
- Astellas Pharma US Inc$281
- Abbott$252
- GSK$181
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,97097%
- Education$943%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 19 | $429 |
| Novo Nordisk | 13 | $428 |
| AstraZeneca | 10 | $327 |
| Astellas Pharma US Inc | 7 | $281 |
| Abbott | 4 | $252 |
| GSK | 6 | $181 |
| Pfizer | 8 | $149 |
| Xeris Pharmaceuticals, Inc. | 6 | $122 |
| Lilly USA, LLC | 6 | $112 |
| Harmony Biosciences LLC | 4 | $92 |
| Paratek Pharmaceuticals, Inc. | 3 | $73 |
| Jazz Pharmaceuticals Inc. | 3 | $72 |
| Amgen | 4 | $72 |
| Medtronic | 4 | $56 |
| IBSA Pharma Inc. | 3 | $53 |
| Smith+Nephew | 3 | $48 |
| Lundbeck LLC | 2 | $37 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $35 |
| Aimmune Therapeutics, Inc. | 2 | $34 |
| Dexcom, Inc. | 2 | $32 |
| Johnson & Johnson | 1 | $32 |
| Azurity Pharmaceuticals, Inc. | 1 | $25 |
| Solventum Corporation | 1 | $22 |
| Bayer | 1 | $21 |
| Vivus LLC | 1 | $18 |
| Insulet Corporation | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$176
- Veozah$127
- Wegovy$114
- VRAYLAR$111
- NUCALA$106
How this compares
$3,064 in reported general payments places this provider in the 75th percentile of 1,490 medical providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 80 | $125,109 |
| MounjaroTirzepatide | 39 | $58,186 |
| Tresiba Flextouch U-200Insulin Degludec | 40 | $41,089 |
| EliquisApixaban | 32 | $36,946 |
| JardianceEmpagliflozin | 23 | $30,055 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $21,286 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $18,764 |
| FarxigaDapagliflozin Propanediol | 19 | $17,531 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $16,587 |
| MyrbetriqMirabegron | 13 | $16,530 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $15,596 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 11 | $9,324 |
| Novolog FlexpenInsulin Aspart | 20 | $6,493 |
| Humalog Kwikpen U-100Insulin Lispro | 26 | $5,071 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 11 | $2,807 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $428 | $125,10980 claims |
| Lilly USA, LLCMounjaro | $112 | $58,18639 claims |
| PfizerEliquis | $149 | $36,94632 claims |
| GSKTrelegy Ellipta, Arexvy | $181 | $19,39424 claims |
| AstraZenecaFarxiga | $327 | $17,53119 claims |
| Astellas Pharma US IncMyrbetriq | $281 | $16,53013 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $17 | $9,32411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,490 medical providers in Texas.
Other medical in Midland
- Jose de la CerdaSan Antonio$1.1M
- Mark DavisFort Worth$1M
- Joey Dixon-JulianBoerne$458K
- Terry FaleyeKingwood$243K
- Kimberly PoarchDallas$166K
- Erin DuhaimeDallas$150K
- Courtney AldridgeSan Antonio$129K
- Shakira CabreraSan Antonio$116K
- Danny DeckardDallas$101K
- Janine ShinnDallas$84K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.